依达拉奉与尼莫地平治疗高血压脑出血的效果观察

The effect of edaravone and nimodipine on hypertensive cerebral hemorrhage was observed

目的探究依达拉奉与尼莫地平治疗高血压脑出血的效果。方法选择2016年1月—2018年1月收治的118例高血压脑出血患者临床资料进行分析,将行常规综合治疗者设作对照组(59例),于此基础上结合依拉达奉、尼莫地平治疗者设作研究组(59例),比较两组临床疗效、血浆内皮素(ET-1)水平、水肿与血肿体积、神经缺损功能(NIHSS)评分。结果对照组治疗总有效率71. 18%较研究组显著低(P <0. 05);两组治疗后血浆ET-1水平、水肿与血肿体积均较治疗前低,且以研究组血浆ET-1(73. 22±8. 35) ng/L等指标降低幅度更大(P <0. 01);研究组与对照组治疗前NIHSS评分未显示高度差异(P> 0. 01),以研究度治疗2周、4周后NIHSS评分(12. 42±4. 06)分、(7. 51±1. 83)分显著高于对照组(P <0. 01)。结论高血压脑出血患者经尼莫地平及依拉达奉协同治疗可有效促疗效提升,神经功能改善。

Objective：to investigate the effect of edaravin and nimodipine in the treatment of hypertensive cerebral hem- orrhage. Method choosing in January 2016 January 2018 118 cases of hypertensive cerebral hemorrhage patients clinical data were analyzed, and the routine comprehensive treatment is set as the control group （ u = 59） , on this basis, combining with lada in, nim horizon healer set for the team （59 cases） , compared two groups of clinical curative effect, the level of plasma endothelin （ET）, edema and hematoma volume, nerve defect score （NIHSS）. Results the total effective rate was 71.18% in the control group （P 〈 0. 05）. After treatment, the plasma ET-1 level, edema and hematoma volume were lower than that of the treatment, and the group of plasma ET-1 （73.22 ± 8.35） ng/L was lower in the study group （P 〈 0. 01 ）. Treatment group and control group before the NIHSS score not shown height difference （P 〉 0. 01 ） , 2 weeks, 4 weeks after treatment at research degrees NIHSS score （12. 42 ± 4. 06）, （7. 51 ± 1.83） is significantly higher than the control group （ P 〈 0. 01 ）. Conclusion patients with hypertensive intracerebral hemorrhage can effectively promote curative effect and improve neurologic function through the synergistic treatment of nimodipine and eladar.